Expanding knowledge of the biology of breast cancers has led into an era of therapeutic uncertainty. The role of radical mastectomy is no longer unassailable. The value of postoperative radiation is dubious at best, that of chemotherapy is being confirmed. And oncologists are becoming increasingly appreciative of the importance of lymph-node and estrogen-receptor status in a patient's prognosis.